Cargando…
Safety and Immunogenicity of rSh28GST Antigen in Humans: Phase 1 Randomized Clinical Study of a Vaccine Candidate against Urinary Schistosomiasis
BACKGROUND: Treatment of urinary schistosomiasis by chemotherapy remains challenging due to rapid re-infection and possibly to limited susceptibility to praziquantel treatment. Therefore, therapeutic vaccines represent an attractive alternative control strategy. The objectives of this study were to...
Autores principales: | Riveau, Gilles, Deplanque, Dominique, Remoué, Franck, Schacht, Anne-Marie, Vodougnon, Hubert, Capron, Monique, Thiry, Michel, Martial, Joseph, Libersa, Christian, Capron, André |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389022/ https://www.ncbi.nlm.nih.gov/pubmed/22802974 http://dx.doi.org/10.1371/journal.pntd.0001704 |
Ejemplares similares
-
Safety and efficacy of the rSh28GST urinary schistosomiasis vaccine: A phase 3 randomized, controlled trial in Senegalese children
por: Riveau, Gilles, et al.
Publicado: (2018) -
Contribution of the Gut Microbiota in P28GST-Mediated Anti-Inflammatory Effects: Experimental and Clinical Insights
por: Foligné, Benoît, et al.
Publicado: (2019) -
Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn’s Disease: A Pilot Study (ACROHNEM)
por: Capron, Monique, et al.
Publicado: (2019) -
The schistosome glutathione S-transferase P28GST, a unique helminth protein, prevents intestinal inflammation in experimental colitis through a Th2-type response with mucosal eosinophils
por: Driss, V, et al.
Publicado: (2016) -
Treatment with P28GST, a schistosome-derived enzyme, after acute colitis induction in mice: Decrease of intestinal inflammation associated with a down regulation of Th1/Th17 responses
por: Sarazin, Aurore, et al.
Publicado: (2018)